Vivo Bio Tech Ltd.

Vivo Bio Tech Ltd., a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a marked deterioration in its financial performance for the quarter ended March 2026. Despite achieving its highest quarterly net sales to date, the company’s profitability and operational efficiency have sharply declined, prompting a downgrade to a Strong Sell rating by MarketsMOJO as of 1 June 2026.

Vivo Bio Tech Ltd., a micro-cap player in the Pharmaceuticals & Biotechnology sector, has been downgraded from a Sell to a Strong Sell rating as of 1 June 2026. This adjustment reflects deteriorating fundamentals, worsening technical indicators, and a bleak financial trend, signalling heightened risk for investors amid sustained underperformance against benchmarks.

Vivo Bio Tech Ltd., a contract research organisation specialising in drug development and discovery services, reported a shocking net loss of ₹5.16 crores in Q4 FY26, a dramatic reversal from the ₹1.25 crore profit in the previous quarter. The loss, driven by an extraordinary tax charge of ₹5.41 crores representing a staggering 2,164.00% effective tax rate, overshadowed an otherwise improving operational performance with revenue reaching a quarterly high of ₹14.20 crores. The stock plunged 10.67% to ₹24.62 following the results announcement, reflecting investor concern over the deteriorating profitability despite sequential revenue growth of 5.11%.

Vivo Bio Tech Ltd., a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Strong Sell to Sell as of 26 May 2026. This change is primarily driven by a shift in technical indicators, despite ongoing challenges in financial performance and valuation metrics. The company’s stock price currently trades at ₹27.18, down 1.84% on the day, reflecting mixed signals from market participants.

Vivo Bio Tech Ltd., a micro-cap player in the Pharmaceuticals & Biotechnology sector, has been downgraded from a Sell to a Strong Sell rating as of 21 May 2026. This revision reflects deteriorating technical indicators, stagnant financial performance, and subdued valuation metrics, signalling heightened risks for investors amid a challenging market environment.

Vivo Bio Tech Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 15 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 May 2026, providing investors with the latest insights into the company’s performance and outlook.

Vivo Bio Tech Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 15 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 May 2026, providing investors with an up-to-date view of the company's fundamentals, returns, and technical outlook.

Vivo Bio Tech Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 15 April 2026. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 27 April 2026, providing investors with the most up-to-date perspective on the company’s performance and outlook.

Vivo Bio Tech Ltd., a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Strong Sell to Sell as of 15 Apr 2026. This change is primarily driven by a shift in technical indicators, although the company continues to face challenges in financial performance and valuation metrics. The stock price rose 7.63% on the day following the upgrade, reflecting renewed investor interest amid mixed signals.

Vivo Bio Tech Ltd. is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 January 2026. However, all fundamentals, returns, and financial metrics discussed here reflect the stock's current position as of 13 April 2026, providing investors with the latest comprehensive analysis.

Vivo Bio Tech Ltd. is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 02 April 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trend, and technical outlook.

For the fifth consecutive session, Vivo Bio Tech Ltd. has closed lower, slipping to a fresh 52-week low of Rs 21.9 on 30 Mar 2026. This decline comes amid a broader market downturn, but the stock’s underperformance is notably sharper than its sector peers.

Despite a broadly positive market environment, Vivo Bio Tech Ltd. has plunged to a fresh 52-week low of Rs 22.23 on 27 Mar 2026, extending its recent downtrend amid heightened volatility and sector underperformance.

Vivo Bio Tech Ltd. is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 18 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Shares of Vivo Bio Tech Ltd. touched a fresh 52-week low of Rs.23 today, marking a significant decline amid persistent downward momentum. The stock has underperformed its sector and broader market indices, reflecting ongoing concerns about its financial health and market positioning.

Vivo Bio Tech Ltd. is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 05 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.